Treatment with the selective ROCK2 inhibitor KD025 led to statistically significant overall response rates in patients with chronic graft-versus-host disease who have received ≥2 prior lines of systemic therapy.
Investigators are exploring the novel genetic biomarker DGM1 as a potential predictor of benefit from the experimental agent enzastaurin in treatment-naïve patients with high-risk diffuse large B-cell lymphoma.
The FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.
Ixazomib significantly improved progression-free survival as a first-line maintenance therapy compared with placebo in adult patients with multiple myeloma who have not undergone stem cell transplantation, meeting the primary endpoint of the phase III TOURMALINE-MM4 study.
Novel combinations of biologic therapies, third-generation TKIs, and chemotherapy could lead to significantly higher cure rates for adult patients with acute lymphoblastic leukemia, with a number of early stage studies already showing promising results, according to Hagop M. Kantarjian, MD, at the 37th Annual CFS®.
Given that a watch-and-wait approach is a viable option, clinicians must carefully consider disease characteristics when selecting a treatment strategy in newly diagnosed follicular lymphoma.
With a variety of available agents in follicular lymphoma, determining which treatments to choose and how best to sequence them can be challenging.
Gilteritinib demonstrated a higher remission rate and a statistically significant improvement in overall survival compared with salvage chemotherapy in patients with relapsed/refractory acute myeloid leukemia who harbor a FLT3 mutation.
Umbralisib (TGR-1202) met the primary endpoint of overall response rate in the follicular lymphoma cohort of the pivotal phase IIb UNITY-NHL trial, according to TG Therapeutics, Inc., the developer of the PI3K-delta inhibitor.
Treatment with iodine-131 apamistamab led to a high bone marrow transplant rate compared with salvage chemotherapy in elderly patients with relapsed/refractory acute myeloid leukemia.